quemliclustat Updated Oct 24
The next hard catalyst for quemliclustat is the Phase 2 primary completion readout from trial NCT05329766, estimated for January 2027. However, this is a secondary pipeline asset at Arcus, the stock's primary value driver is casdatifan (HIF-2α inhibitor). Watch for topline data from the GI malignancy trial in early 2027, but expect the stock to move more on casdatifan and domvanalimab catalysts than on quemliclustat alone.
- Quemliclustat is being tested in a rational combination with domvanalimab (anti-TIGIT) and zimberelimab (anti-PD-1) plus chemotherapy, a multi-pronged immunotherapy approach targeting multiple immune checkpoints and the adenosine pathway simultaneously.
- The Phase 2 trial (NCT05329766) is fully enrolled (332 patients) and active but not recruiting, meaning data collection is underway with estimated primary completion in January 2027.
- Arcus has strong analyst support, 16 Buy/Strong Buy ratings vs 0 Sell, with a mean price target of $41 (121% upside from $18.54), suggesting the market sees value in the broader pipeline including quemliclustat.
- Quemliclustat is a secondary pipeline asset at Arcus, the company's primary focus and capital allocation is on casdatifan (HIF-2α inhibitor), which received the bulk of the $250M October 2026 offering proceeds. Quemliclustat may be deprioritized if casdatifan requires more resources.
- The Phase 2 trial (NCT05329766) has no posted results yet and the estimated primary completion is January 2027, nearly 5 years after trial start in June 2022, suggesting enrollment or data collection challenges.
- CD73 inhibitors as a class have faced mixed clinical results across the industry, with several programs failing to show clear benefit over standard-of-care checkpoint inhibitors.